(Source: Johnson & Johnson) Combined Fixed-Dose Tablet of Darunavir and Cobicistat Can Help Reduce Number of Pills in a Combination Antiretroviral Treatment Regimen TITUSVILLE, NJ, January 29, 2015 - Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the U.S. Food and Drug Administration (FDA) has approved PREZCOBIX™ (darunavir 800 mg/cobicistat 150 mg) tablets, an HIV-1 protease inhibitor combined with a CYP3A4 inhibitor, for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral agents for treatment-naïve and treatment-experienced adults with no darunavir resistance-associated substitutions.1 PREZCOBIX™ is a once-daily,...
↧